MarketBeat·1d ago
Oura's $15.6 Billion IPO Is Betting Investors See More Than a Smart RingOura Inc. NASDAQ: OURA launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of Sept.
DexCom's accelerating revenue growth (13.1% YoY in 2026Q2) and robust gross margin expansion to 63.4% underscore strong operational execution, driven by expanded CMS coverage and pharmacy channel adoption. The company has significantly deleveraged, cutting tot...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 13.1% YoY in 2026Q2, with gross margin expanding to 63.4% and operating margin reaching 24.3%, reflecting strong operating leverage and disciplined R&D spending.
Dexcom has set the standard in glucose biosensing for 25 years, with best-in-class technologies and continuous product innovation.
The company is expanding its market reach into Type 2 diabetes, driving user growth and broadening its customer base.
Dexcom has significant institutional backing, with top holder Vanguard Group owning 11% of the company, indicating strong investor confidence.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Jul 30, 2026 | $0.70+14.6% vs $0.61 | $1.3B+1.4% vs $1.3B |
Q2 2026 Apr 30, 2026 | $0.56+20.3% vs $0.47 | $1.2B+1.5% vs $1.2B |
Q1 2026 Feb 12, 2026 | $0.68+4.6% vs $0.65 | $1.3B+0.9% vs $1.2B |
Q4 2025 Oct 30, 2025 | $0.61+5.9% vs $0.58 | $1.2B+2.2% vs $1.2B |
Oura Inc. NASDAQ: OURA launched its roadshow on Sept. 21, 2026, targeting a Nasdaq debut under the ticker OURA during the week of Sept.
SAN DIEGO--(BUSINESS WIRE)--Dexcom Promotes Jereme Sylvain to Chief Operating Officer.
DXCM's strong growth, G7 15 Day adoption and CONNECT trial could expand its CGM market opportunity despite reimbursement and competition risks.
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Glenn Boehnlein to its Board of Directors, effective September 10, 2026. Mr. Boehnlein is a highly accomplished healthcare executive and finance leader with more than 20 years of experience in the medical technology industry. Most recently, he served as Vice President and Chief Financial Officer of Stryker Corporation, one of the world's leading medical technology.
Benchmark DXCM against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for DexCom, Inc. (DXCM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $89.53 | $34.55B | 42.84 | 15.6% | 17.94% | 34.5% | — | |
| $103.73 | $180.68B | 27.88 | 5.67% | 13.91% | 12.09% | — | |
| $139.38 | $9.65B | 40.05 | 30.73% | 12.29% | 26.69% | — | |
| $17.50 | $1.2B | -5.76 | 7.93% | -6.08% | -45.97% | — | |
| $16.67 | $1.93B | -13.66 | 8.28% | -21.25% | -44% | — | |
| $20.98 | $1.55B | 6.36 | 18.52% | 80.56% | 30.03% | — |
DexCom, Inc. (DXCM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
DexCom, Inc. (DXCM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Jul 30, 2026·SEC
May 28, 2026·SEC
May 15, 2026·SEC
Get notified when DXCM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
DexCom, Inc. (DXCM) stock FAQ — growth, dividends, profitability & financials explained
DexCom, Inc. (DXCM) reported $4.97B in revenue for fiscal year 2025.
DexCom, Inc. (DXCM) grew revenue by 15.6% over the past year. This is strong growth.
Yes, DexCom, Inc. (DXCM) is profitable, generating $999.7M in net income for fiscal year 2025 (17.9% net margin).
DexCom, Inc. (DXCM) has a return on equity (ROE) of 34.5%. This is excellent, indicating efficient use of shareholder capital.
DexCom, Inc. (DXCM) generated $1.41B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
